ArticleFrontiers in oncology2025
Global spatio-temporal evolution and health inequalities in high BMI-associated kidney cancer burden from 1990 to 2021 and burden prediction to 2040.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The primary cancer of the urinary system, kidney cancer is becoming more common worldwide and is linked to a high body mass index (BMI). Although 20% of kidney cancer cases are caused by obesity, current research data on the global burden of the disease and its trends across population groups are scarce, especially as predicted by 2040. Method: We examined age-standardized mortality rates (ASMR), disability-adjusted life years (DALYs), and sociodemographic index (SDI) using Global Burden of Disease (GBD 2021) data from 204 nations and territories. joinpoint regression revealed changes in temporal trends and age-period-cohort (APC) modeling separated the effects of age, period, and cohort. Finally, we project the disease burden to 2040. Result: From 1990 to 2021, high BMI-related kidney cancer deaths increased by 2.67-fold, and DALYs rose by 66.1%. In 2021, the ASMR for high BMI-associated kidney cancer was 0.38 (95% per 10 0,000 UI: 0.12-0.52) and the ASDR was 8.99 per 100,000 (95% UI: 3.68-14.51). Significant heterogeneity was observed in gender and age, with a significantly higher male burden concentrated in the 55-79 year group. The main burden is concentrated in the high SDI region, including South Latin America, North America, Europe and North Asia. Over 30 years, the burden of high BMI-associated kidney cancer gradually increased, especially in low SDI areas, while high SDI areas showed a decreasing trend after 2016. The global disease burden of high BMI-associated kidney cancer burden grew fastest between 2000 and 2010, began to decline in 2016, and will rebound in 2030. Conclusion: The global burden of high BMI-associated kidney cancer burden has surged since 1990. Although it showed a downward trend in 2016, it is expected to rebound by 2030. Significant differences exist across regions, genders, and age groups. Policymakers must prioritize obesity prevention, adopt gender-specific strategies, enhance early detection in older populations, and address issues of socioeconomic inequality and unequal distribution of healthcare resources to tackle this public health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.